These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 21782369)

  • 1. Characterization and relative response factor determination of process related impurity in Naproxen by nuclear magnetic resonance spectroscopy.
    Iqbal MY; Rao KM; Sridhar G; Raju PP; Deshpande GR; Babu JM
    J Pharm Biomed Anal; 2011 Nov; 56(3):484-90. PubMed ID: 21782369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of a novel impurity in bulk drug eprosartan by ESI/MS(n) and NMR.
    Sun C; Wu J; Wang D; Pan Y
    J Pharm Biomed Anal; 2010 Feb; 51(3):778-83. PubMed ID: 19864105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of LC/MS, GC/MS, and LC/NMR hyphenated techniques to identify a drug degradation product in pharmaceutical development.
    Pan C; Liu F; Ji Q; Wang W; Drinkwater D; Vivilecchia R
    J Pharm Biomed Anal; 2006 Feb; 40(3):581-90. PubMed ID: 16242883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification, isolation, characterization and response factor determination of process-related impurity in meprobamate drug substance.
    Karthikeyan K; Arularasu GT; Murali V; Pillai KC
    J Pharm Biomed Anal; 2011 Jan; 54(1):208-12. PubMed ID: 20727702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isolation and characterization of a potential process related impurity of phenazopyridine HCl by preparative HPLC followed by MS-MS and 2D-NMR spectroscopy.
    Rao RN; Maurya PK; Raju AN
    J Pharm Biomed Anal; 2009 Jul; 49(5):1287-91. PubMed ID: 19376664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification, isolation and characterization of a new degradation product in sultamicillin drug substance.
    Kumar VJ; Gupta PB; Kumar KS; Ray UK; Sreenivasulu B; Kumar GS; Rao KR; Sharma HK; Mukkanti K
    J Pharm Biomed Anal; 2011 Feb; 54(3):582-7. PubMed ID: 20934824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification, isolation and characterization of potential degradation product in risperidone tablets.
    Bharathi Ch; Chary DK; Kumar MS; Shankar R; Handa VK; Dandala R; Naidu A
    J Pharm Biomed Anal; 2008 Jan; 46(1):165-9. PubMed ID: 17981421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and characterization of new impurity in didanosine.
    Srinivasa Rao DV; Srinivas N; Bharathi Ch; Prasad ChS; Dandala R; Naidu A
    J Pharm Biomed Anal; 2007 Nov; 45(3):516-20. PubMed ID: 17624711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural identification and characterization of impurities in ceftizoxime sodium.
    Bharathi Ch; Prasad ChS; Bharathi DV; Shankar R; Rao VJ; Dandala R; Naidu A
    J Pharm Biomed Anal; 2007 Jan; 43(2):733-40. PubMed ID: 16950586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and characterization of potential impurities of valsartan, AT1 receptor antagonist.
    Sampath A; Reddy AR; Yakambaram B; Thirupathi A; Prabhakar M; Reddy PP; Reddy VP
    J Pharm Biomed Anal; 2009 Oct; 50(3):405-12. PubMed ID: 19560892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NMR and mass spectrometric characterization of vinblastine, vincristine and some new related impurities--part II.
    Háda V; Dubrovay Z; Lakó-Futó A; Galambos J; Gulyás Z; Aranyi A; Szántay C
    J Pharm Biomed Anal; 2013 Oct; 84():309-22. PubMed ID: 23177164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification, synthesis, isolation and spectral characterization of potential impurities of montelukast sodium.
    Saravanan M; Siva Kumari K; Pratap Reddy P; Naidu MN; Moses Babu J; Srivastava AK; Lakshmi Kumar T; Chandra Sekhar BV; Satyanarayana B
    J Pharm Biomed Anal; 2008 Nov; 48(3):708-15. PubMed ID: 18755563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation of amodiaquine bulk drug impurities by liquid chromatography/ion trap mass spectrometry.
    Dongre VG; Karmuse PP; Ghugare PD; Kanojiya SK; Rawal S
    Rapid Commun Mass Spectrom; 2008 Jul; 22(14):2227-33. PubMed ID: 18543378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification, isolation and characterization of impurities of clindamycin palmitate hydrochloride.
    Bharathi Ch; Jayaram P; Sunder Raj J; Saravana Kumar M; Bhargavi V; Handa VK; Dandala R; Naidu A
    J Pharm Biomed Anal; 2008 Dec; 48(4):1211-8. PubMed ID: 18947955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impurity profile study of dutasteride.
    Satyanarayana K; Srinivas K; Himabindu V; Mahesh Reddy G
    Pharmazie; 2007 Oct; 62(10):743-6. PubMed ID: 18236777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and characterization of a principal oxidation impurity in clopidogrel drug substance and drug product.
    Mohan A; Hariharan M; Vikraman E; Subbaiah G; Venkataraman BR; Saravanan D
    J Pharm Biomed Anal; 2008 May; 47(1):183-9. PubMed ID: 18313249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The application of LC-NMR and LC-MS for the separation and rapid structure elucidation of an unknown impurity in 5-aminosalicylic acid.
    Novak P; Tepes P; Fistrić I; Bratos I; Gabelica V
    J Pharm Biomed Anal; 2006 Mar; 40(5):1268-72. PubMed ID: 16253464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of Five Oxidative Degradation Impurities and One Process Impurity of Suvorexant Drug Substance by LC-MS/MS, HR-MS and 1D, 2D NMR: Validation of Suvorexant Drug Substance and Process Impurities by HPLC and UPLC.
    Rajana N; Devi DR; Kumar Reddy DN; Babu JM; Basavaiah K; Balakumaran K
    J Chromatogr Sci; 2020 Apr; 58(5):433-444. PubMed ID: 32134104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural elucidation of a process-related impurity in ezetimibe by LC/MS/MS and NMR.
    Raman B; Sharma BA; Butala R; Ghugare PD; Kumar A
    J Pharm Biomed Anal; 2010 May; 52(1):73-8. PubMed ID: 20079995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolation and characterization of benazepril unknown impurity by chromatographic and spectroscopic methods.
    Shinde VR; Trivedi A; Upadhayay PR; Gupta NL; Kanase DG; Chikate RC
    J Pharm Biomed Anal; 2006 Sep; 42(3):395-9. PubMed ID: 16765551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.